Microbial enzymes and macromolecules

Microbial enzymes and macromolecules encompass a vast array of biological entities that serve as the primary targets for antimicrobial therapy. These include essential enzymes involved in metabolic pathways, such as dihydrofolate reductase and DNA gyrase, as well as structural macromolecules like peptidoglycan and ribosomal subunits [PubMed: 25231041]. These targets are critical for the survival, replication, and virulence of pathogens including bacteria, viruses, fungi, and parasites. Drugs targeting these components, such as antibiotics, antivirals, and antifungals, are designed to exploit the biochemical differences between microbial cells and human host cells to achieve selective toxicity [StatPearls: NBK441868]. For example, beta-lactams inhibit penicillin-binding proteins to disrupt bacterial cell wall synthesis, while protease inhibitors target viral enzymes to prevent maturation [NIH: PMC7120349]. However, the broad nature of this category means it includes thousands of distinct molecular targets across different species. Consequently, while these molecules are therapeutic targets, the term itself refers to a functional class rather than a specific, individual drug target.

Other names

Microbial targetsPathogen-associated macromoleculesAntimicrobial targetsBacterial and viral enzymes

Mechanisms include the inhibition of cell wall synthesis (e.g., beta-lactams), inhibition of protein synthesis by binding to ribosomal subunits (e.g., macrolides), inhibition of nucleic acid synthesis and replication (e.g., fluoroquinolones), and disruption of metabolic pathways like folic acid synthesis (e.g., sulfonamides) [StatPearls: NBK441868].